SenzaGen (SENZA) Life Science Summit 2025 summary

Company growth and financial performance

• Achieved 600% growth since 2021, with nearly 400% organic from the GARD business.

• Maintained a stable gross margin around 66-67% and reached break-even in Q3.

• Q3 sales reached SEK 15.2 million, up 15% year-over-year, with GARD platform sales up 12%.

• Added 10 new customers in Q3, with significant orders from the US and technology sector.

• 85% of revenue in Q3 came from recurring customers.

Business model, market, and competitive landscape

• Operates as a group of three companies specializing in non-animal toxicology and efficacy testing.

• Serviceable market estimated at $500 million, with overall non-animal testing market at $13 billion.

• Market growth projected at 6.5–9.5% annually, driven by regulatory changes and scientific advances.

• Main competitors include Charles River, Eurofins, and niche players, but GARD platform is unique in using genomics and AI.

• Industry agnostic, serving pharma, medical device, cosmetic, and chemical sectors.

Technology and regulatory progress

• GARD platform uses genomics and machine learning to assess skin sensitization via human dendritic cells.

• Received OECD TG 497 regulatory approval, enabling broader regulatory compliance.

• Working to establish GARD as the first ISO standard method for non-animal skin sensitization testing.

• Platform measures 196 biomarkers and uses AI algorithms for classification.

• GARD is positioned as a next-generation method compared to first-generation non-animal tests.